Altimmune, Inc. (NASDAQ:ALT) Q2 2025 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to the Altimmune Second Quarter 2025 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Altimmune Inc. (ALT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 0 | $0 | 0% | |
| 2. | Renaissance Technologies Jim Simons | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.78 | 1,000 | $5,784.50 | 1,000 | 2025-03-17 | Filing | |
| $5.20 | 10,000 | $51,996.00 | 10,000 | 2025-03-13 | Filing | |
| $2.88 | 300 | $862.50 | 29,785 | 2023-08-15 | Filing | |
| $4.27 | 9,000 | $38,430.00 | 29,484 | 2023-03-23 | Filing | |
| $4.31 | 10,000 | $43,140.00 | 22,010 | 2023-03-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.88 | 8,184 | $56,305.92 | 55,524 | 2024-08-19 | Filing | |
| $6.93 | 7,827 | $54,241.11 | 41,958 | 2024-08-19 | Filing | |
| $15.00 | 2,714 | $40,710.00 | 2,771 | 2022-08-12 | Filing | |
| $15.01 | 20,000 | $300,268.00 | 8,498 | 2022-12-22 | Filing | |
| $20.02 | 20,000 | $400,322.00 | 236,797 | 2022-08-31 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 0 | $0 | 0% | |
| 2. | 0 | $0 | 0% | |
| 3. | 0 | $0 | 0% | |
| 4. | 0 | $0 | 0% | |
| 5. | 0 | $0 | 0% |
News See All
Altimmune (ALT) Reports Positive Phase 2b Results for Pemvidutide in MASH Trial
Altimmune, Inc. (NASDAQ:ALT) is one of Goldman Sachs’ top penny stock picks.
Goldman Sachs Penny Stocks: Top 12 Stock Picks
In a June 24, 2025, podcast, Goldman Sachs’ Christian Mueller-Glissmann and Alexandra Wilson-Elizondo examined the dynamics driving markets.
13 Best Multibagger Stocks to Invest in Now
The global economic and geopolitical environment in 2025 is marked by uncertainty, trade tensions, and shifting monetary policies.
Altimmune, Inc. (NASDAQ:ALT) Q1 2025 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to Altimmune First Quarter 2025 Financial Results Conference Call. After the speakers' presentation, there will be a question-and-answer session.
10 Best Short Squeeze Stocks to Buy According to Analysts
Stock market trading has an ever-changing environment. Short squeeze is among the few phenomena capable of capturing and holding the attention of such markets.
Altimmune, Inc. (NASDAQ:ALT) Q4 2024 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to Altimmune Fourth Quarter and Full Year 2024 Financial Results Conference Call. As a reminder, this call is being recorded.
8 Stocks on Jim Cramer's Radar
Jim Cramer, the host of Mad Money, recently shared some investment guidelines based on his 40 years of experience.
11 Reddit Stocks with Biggest Upside Potential
Paul Hickey, Bespoke co-founder, together with Dana D'Auria, Envestnet co-chief Investment Officer, joined CNBC's 'Closing Bell: Overtime' on November 12 to discuss the market's reaction to the election...
Altimmune, Inc. (NASDAQ:ALT) Q3 2024 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to Altimmune, Inc. Third Quarter 2024 Financial Results Conference Call. At this time all participants’ are in a listen-only mode.